SEC Form 4 · accession 0001209191-19-011175
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Derrell Porter
Officer — SVP, Head of Global Commercial
Period of report
Feb 15, 2019
Accepted (ET)
Feb 19, 2019 · 5:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2019 | M | 4,000 | $14.30 | A | 27,597 | D | |
| Common Stock | Feb 15, 2019 | S | 5,909 | $40.00 | D | 21,688 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $14.30 | Feb 15, 2019 | M | 4,000 | D | — | May 10, 2024 | Common Stock | 4,000 | 109,666 | D |
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted November 9, 2018.
- F225% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter.